Archive: Company News
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T
— Preclinical, Translational and Clinical Trial Posters for TK-8001 Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
— Plan to Initiate a First-in-Human, Phase 1/2 Trial in Early 2022
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningful anti-tumor activity and enhanced engraftment as compared to human donor derived TCRs. Read more…
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
– Promising data presented at Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
– Multi-functional agent targeting three innate immune checkpoint receptors
– Potential as monotherapy and combination therapy for solid tumors and blood cancers
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced promising data for the Company´s lead program IOS-1002 (formerly iosH2). Read more…
Glooko Announces Collaboration with Novo Nordisk for European Connected Pen Launches
— Research Finds Connected Pens Significantly Reduce Missed Doses and Improves Time in Recommended Glucose Range —
Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, announced a strategic collaboration with Novo Nordisk that will benefit people with diabetes in Germany, and other European markets, through the development of connected insulin pen solutions. Through this collaboration, the companies are integrating two new connected or “smart” insulin pens, NovoPen® 6 and NovoPen Echo® Plus, with Glooko’s mobile apps and cloud-based platforms.
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
– Expanded investor syndicate strengthens the company’s financial position and investor base
Pan Cancer T B.V., a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid tumors, announced today the closing of an extended seed investment round. All current shareholders participated in the round, with Thuja Capital joining as a new investor. The undisclosed proceeds add to the initial seed capital financing announced earlier this year. The Company’s syndicate of experienced life science venture capital investors now includes Van Herk Ventures, Swanbridge Capital, and Thuja Capital as well as founding shareholder Erasmus MC.